PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study

Authors: Loulu Gao, Lin Tang, Jieqiong Peng, Zixuan Hu, Jing Yang, Bo Liu

Source: Frontiers in Immunology, Vol 15 (2024)

Subject Terms: PD-1 inhibitors, chemotherapy, esophageal squamous cell carcinoma, first-line treatment, real-world study, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353445/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/dc1b9ea8d0c441a7a4a1ed0797bc1d26

Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis

Authors: Loulu Gao, Lin Tang, Zixuan Hu, Jieqiong Peng, Xiaoqian Li, Bo Liu

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: colorectal cancer, third-line, neoplasm metastasis, network meta-analysis (NMA), treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1269203/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/b9fe014dbc1a4da19d64661ba7198599

Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report

Authors: Jieqiong Peng, Qiang Zhu, Ziru Peng, Zhen Chen, Yuantao Liu, Bo Liu

Source: Frontiers in Immunology, Vol 13 (2022)

Subject Terms: PD-1/CTLA-4 bispecific, AK104/cadonilimab, HER-2 positive, complete response, advanced gastroesophageal junction cancer, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1049518/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/3a9480665b894f07bce39acb264827e9